Pain mitigation company Calmare Therapeutics said yesterday it won a general supply order contract from the U.S. Department of Defense for an estimated $15 million over the next 60 months.
The Fairfield, Conn.-based company’s flagship product is its Calmare Pain Therapy Device, which is designed as a non-invasive and non-addictive neuropathic pain treatment modality, and has FDA 510(k) clearance.
“This is a momentous occasion in our company’s history as a military contractor. Our military contracts team has helped us overcome many obstacles to reach this significant milestone. We look forward to broadening our presence in the government contract space over the short- and long- term,” CEO Conrad Mir said in a press release.
Calmare said its pain mitigation therapy is designed to treat chronic neuropathic pain patients, offering prolonged pain mitigation for 3 to 4 months, with certain patients experiencing full pain elimination up to a year or more.